Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM

By / / Finance / 1 minute of reading


ywAAAAAAQABAAACAUwAOw==
https://www.tipranks.com/news/the-fly/gain-therapeutics-gt-02287-study-to-deliver-positive-findings-says-roth-mkm

Roth MKM keeps a Buy rating and $7 price target on Gain Therapeutics (GANX) after the company received approval from Australian regulators to begin GT-02287 evaluation in Parkinson’s disease patients. The firm believes that the Phase 1b study will deliver positive findings regarding safety, preliminary biochemical efficacy, and tolerability, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Read More on GANX:



Source link

About The Author

Avatar of Dena Holloway
Dena Holloway is a writer, editor, and content creator based in the United States. She has written for a variety of publications, including Men With Wings Press, where she covers arts, automotive, travel, and fashion. She's also a certified yoga instructor and works as a freelance copywriter.

Start typing and press enter to search

Scroll to Top